Expression of endothelin(A) receptors in human gliomas and meningiomas, with high affinity for the selective antagonist PD156707.
OBJECTIVE
Endothelin (ET) immunoreactivity, ET production, and specific ET receptors have been identified in the brain. Changes in ET concentration or receptor expression have been implicated in the pathophysiological changes in vasospasm after subarachnoid hemorrhage and in cerebral neoplasia. In this study, we have characterized the ET(A) and ET(B) receptor subtypes present in human normal cerebral cortex (NCC) and two common central nervous system tumors, i.e., meningioma (MNG) and glioblastoma multiforme (GBM). A knowledge of the ET receptor subtypes present may provide a novel therapeutic target for newly developed ET antagonists.


METHODS
Saturation, competition, and autoradiographic studies were performed with the subtype-specific radioligands 125I-PD151242 and 125I-BQ3020, to characterize the ET(A) and ET(B) receptors present in NCC, MNG, and GBM.


RESULTS
NCC expresses high-affinity ET(A) receptors on pial and intraparenchymal vessels and high-affinity ET(B) receptors on glia and neurons. MNGs express mainly (85%) high-affinity ET(A) receptors in a diffuse pattern, whereas GBMs express high-affinity ET(A) receptors on the neovasculature and ET(B) receptors on the nonvascular elements. The ET antagonist PD156707 (Kd = 0.059 nmol/L) showed a higher affinity for the ET(A) receptor subtype than did bosentan (Kd = 1.1 nmol/L).


CONCLUSIONS
ET(A) receptors are expressed in high concentrations in MNGs and in the vasculature of NCC and GBMs. The ET(A)-selective antagonist PD156707 may be of potential therapeutic value in vascular and neoplastic diseases of the central nervous system.
Academic Department of Neurosurgery, University of Cambridge, Addenbrooke's Hospital, United Kingdom.
S P
SP
Harland
R E
RE
Kuc
J D
JD
Pickard
A P
AP
Davenport
D001345:Autoradiography; D001932:Brain Neoplasms / Q000473:pathology*; D002540:Cerebral Cortex / Q000473:pathology; D004149:Dioxoles; D065128:Endothelin Receptor Antagonists; D005909:Glioblastoma / Q000473:pathology*; D006801:Humans; D008577:Meningeal Neoplasms / Q000473:pathology*; D008579:Meningioma / Q000473:pathology*; D044022:Receptor, Endothelin A; D017466:Receptors, Endothelin / Q000032:analysis*
D004149:Dioxoles; D065128:Endothelin Receptor Antagonists; C093321:PD 156707; D044022:Receptor, Endothelin A; D017466:Receptors, Endothelin